• Itaconic Acid-Mediated TBK1 Alkylation Limits Type I IFN Res

  2026-04-22

  Chai et al. (2025) uncover a direct metabolic-immune axis in which IRG1-derived itaconic acid alkylates TBK1, disrupting its dimerization and restraining excessive type I interferon (IFN-I) signaling. This mechanistic insight identifies new avenues for controlling hyperinflammation and highlights metabolic feedback as a regulator of innate immunity.

• Lipid Nanoparticle Delivery of ABE8e Enables COL7A1 Correcti

  2026-04-22

  This study demonstrates targeted correction of COL7A1 mutations in dystrophic epidermolysis bullosa (DEB) fibroblasts using adenine base editor ABE8e delivered via lipid nanoparticles (LNPs). The research highlights a non-viral, RNA-based genome editing approach with high efficiency and minimal off-target effects, informing future therapeutic strategies for inherited skin disorders.

• CTDNEP1-NEP1R1 Complex: Differential Roles in ER Lipid Regul

  2026-04-21

  This study elucidates how the regulatory subunit NEP1R1 differentially modulates CTDNEP1 stability and function in the endoplasmic reticulum (ER), impacting lipid synthesis and storage. The findings clarify mechanisms maintaining lipid homeostasis and offer new perspectives on ER membrane expansion versus lipid droplet biogenesis.

• Nimbolide-Mediated E3 Ligase Targeting for Protein Degradati

  2026-04-21

  Spradlin et al. uncover nimbolide’s covalent targeting of E3 ligase RNF114, revealing a new mechanism for selective protein degradation in cancer cells. Their chemoproteomic approach provides a blueprint for leveraging natural products to expand the toolkit for targeted protein degradation.

• Ferroptosis-Related lncRNA Signature Predicts Pancreatic Can

  2026-04-20

  This study introduces a rigorously validated prognostic signature based on nine ferroptosis-related long non-coding RNAs for pancreatic adenocarcinoma. The signature enhances survival prediction and reveals links between ferroptosis, immune infiltration, and therapy response, providing new biomarkers and targets for cancer biology research.

• Optimizing Cancer Cell Assays with M344: Scenario-Driven Ins

  2026-04-20

  This article offers scenario-based guidance for biomedical researchers and technicians optimizing cell viability, proliferation, and cytotoxicity workflows with M344 (SKU A4105). Grounded in recent peer-reviewed data and real laboratory challenges, it demonstrates how M344’s potent and selective HDAC inhibition supports reproducible results in oncology and HIV-1 latency research.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Im

  2026-04-19

  This study introduces a novel assembloid model integrating matched tumor organoids and stromal cell subpopulations from gastric cancer patients. By recapitulating tumor microenvironment complexity, the model enables detailed investigation of drug responses, biomarker profiles, and resistance mechanisms, advancing preclinical and personalized research.

• M344: Precision Histone Deacetylase Inhibitor for Cancer Res

  2026-04-18

  M344, a potent and cell-permeable histone deacetylase inhibitor, enables highly tunable epigenetic modulation, supporting advanced workflows in cancer biology and HIV-1 latency research. This article distills actionable protocols, troubleshooting guidance, and cross-domain insights to maximize the compound’s translational impact.

• Gap26 Connexin 43 Mimetic Peptide: Protocols and Application

  2026-04-17

  Gap26, a selective connexin 43 mimetic peptide, empowers researchers to precisely modulate gap junction signaling in neurobiology and vascular smooth muscle studies. This article navigates from validated workflows to troubleshooting, leveraging cutting-edge findings to optimize experimental design.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-16

  Schwartz’s dissertation introduces a refined framework for assessing anti-cancer drug responses by disentangling proliferation arrest from cell death in vitro. This approach improves mechanistic insight and assay interpretability, supporting the rational development and evaluation of targeted therapies.

• Hydrocortisone: Glucocorticoid Hormone in Advanced Inflammat

  2026-04-15

  Hydrocortisone (CAS 50-23-7) is the gold standard glucocorticoid hormone for dissecting inflammation and stress response mechanisms in both cellular and animal research. This guide details robust experimental workflows, troubleshooting strategies, and highlights recent innovations that maximize scientific rigor and translational impact.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy & C

  2026-04-14

  RapaLink-1 stands as a third-generation mTOR inhibitor, uniquely enabling both robust cancer pathway inhibition and precise induction of embryonic dormancy in vitro. By overcoming resistance mutations and supporting innovative, noninvasive workflows, it serves as a critical tool for researchers in oncology and developmental biology.

• Vacuolin-1 and the Future of Lysosomal Exocytosis Inhibition

  2026-04-13

  This thought-leadership article examines Vacuolin-1’s mechanistic and translational value as a lysosomal exocytosis inhibitor. It integrates insights from recent cartilage pathology models, highlights best-practice assay design, and offers strategic guidance for translational researchers seeking to unravel lysosome-mediated disease mechanisms. The piece bridges foundational biological rationale with actionable experimental frameworks and concludes with a forward-looking perspective grounded in validated evidence.

• Bazedoxifene: Mechanistic Depth and Strategic Impact in Oste

  2026-04-13

  This thought-leadership article unpacks Bazedoxifene’s dual ERα/ERβ modulation, its tissue-selective actions, and its translational utility in osteoporosis treatment research. Integrating mechanistic insights, clinical evidence, and strategic workflow guidance, it empowers researchers to harness Bazedoxifene for both experimental and therapeutic advancement. The piece uniquely bridges rigorous protocol recommendations with a forward-looking perspective on osteoporosis management, while connecting with APExBIO’s validated product offering and highlighting how this discourse extends beyond conventional product pages.

• Mitochondrial Calcium Signaling Represses Ferroptosis in Tum

  2026-04-12

  This study demonstrates that mitochondrial calcium uptake via the MCU modulates ferroptosis suppression by promoting GPX4 acetylation, revealing a direct link between calcium signaling, mitochondrial metabolism, and cell death resistance in cancer. The findings inform strategies for targeting metabolic vulnerabilities in tumor cell metabolism studies and apoptosis assays.

16147 records 1/1077 page Next 12345 下5页 Last page